A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ReShape Duo balloon
Diet counseling
Exercise counseling
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring obesity, weight loss
Eligibility Criteria
Inclusion criteria:
- Patients 21 to 60 years of age
- Body Mass Index (BMI) ≥ 30 kg/m^2 and ≤ 40 kg/m^2
- At least 5 years of obesity (with BMI ≥ 30)
- Stable weight, defined as a subject who has not gained or lost ≥ 5% of body weight in the 3 months preceding the screening assessment
Failure to lose weight, within the 36 months preceding the screening date, after participation in either of the following:
- A medically or commercially supervised weight loss program involving regular counseling regarding both diet and exercise.
- Use of a United States Food and Drug Administration (FDA)-approved diet drug
- The presence of one or more obesity-related comorbid conditions
- Willing and able to provide Informed Consent
- Willing and able to comply with study procedures and visit schedules as specified by the protocol
If female, the patient must
- be postmenopausal for at least 1 year OR
- be surgically sterile, OR
- if of child bearing potential, must be practicing birth control, be willing to avoid pregnancy for the year of study participation, have a negative serum pregnancy test at screening, and a negative urine pregnancy test at baseline
- Residing within a reasonable distance from the Investigator's treating office and able and willing to travel to the Investigator's office to complete all routine follow-up visits.
Exclusion criteria:
- History of and/or ongoing clinically significant conditions or disorders of the gastrointestinal (GI) tract
- Clinically significant and uncontrolled/unstable hepatic, reproductive, gastrointestinal, renal, hematologic, pulmonary, neurologic, psychiatric, respiratory, endocrine, or cardiovascular system diseases
- Significant acute and/or chronic infections of any kind.
- Severe coagulopathy, hepatic insufficiency or cirrhosis
- Uncontrolled or severe asthma, or any asthma requiring or likely to require inhaled steroid therapy during the anticipated duration of trial participation
- Severe obstructive sleep apnea
- Incompletely controlled hypothyroidism or hyperthyroidism
- Severe systemic disease [consistent with an ASA (American Society of Anesthesia) Physical Status Classification Score of 3 or greater]
- Eating disorders, especially binge eating
- Inability to walk 200 yards without assistance
- Known allergies to any of the device materials or accessories, i.e. silicone, methylene blue, corn starch
- Active drug or alcohol addiction within 12 months of enrollment
- Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of requiring insulin treatment in the following 12 months
- Depressive disorder with total Beck Depression Inventory (BDI) score > 16 points, and/or BDI affective subscale score > 7 points at screening
- Ongoing treatment, or anticipated need for such treatment, with anticoagulants, known gastric irritants such as aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs) or agents that can promote gastrointestinal bleeding, within 1 month prior to enrollment, or unwillingness to forego these medications during the study period
- Participation within 60 days of screening date in previous or ongoing clinical trial or current usage of an investigational drug or device
- Any use of an intragastric device prior to this study.
- Genetically caused obesity, such as Prader-Willi syndrome
- Any prior bariatric surgery or likely to undergo bariatric surgery during study follow-up period
- Concomitant use of, or unwillingness to avoid any use of, weight loss medications, weight loss supplements, weight loss herbal preparations and/or participation in any non-study-related organized weight loss program (commercial or medical) at any time during the study, including online or smart phone applications to track or modify food intake, exercise regimens or weight
- Chronic opiate use (> 3 months continuous use) or likely need for opiate use during study participation
- Contraindication or allergy to, or unwillingness to use, proton pump inhibitor medication throughout study follow-up duration-Pregnancy, breast feeding, or intention of becoming pregnant during the study
- Any screening laboratory values outside of the normal range deemed clinically significant by the Investigator
Anemia defined as either:
- Hemoglobin (Hgb) value for females of < 11.0 g/dl, for males < 12.0 g/dl
- Abnormal red cell indices and iron deficiency
- Smoking cessation within 3 months of study entry or plans to quit smoking during the study
- Major surgery, open biopsy or significant traumatic injury within 3 months prior to enrollment.
- History of significant adverse experience with sedation or anesthesia
- Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with study procedures
Any condition that, in the opinion of the Investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements, including:
- Inability or unwillingness to sign the patient informed consent document.
- Inability to participate in all necessary study activities due to physical or mental limitations.
- Inability or unwillingness to return for all required follow-up visits.
- Employees/family members of ReShape Medical® or any of its affiliates or contractors
- Employees/family members of the Investigator, sub-Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed
- An immediate family member (by marriage or blood relationship) of another subject already enrolled in the REDUCE Pivotal Trial
Endoscopic exclusion criteria:
- Peptic ulcerations
- Clinically significant hiatal hernia (> 3 cm)
- Patulous pyloric channel
- Erosive esophagitis
- Varices
- Angiectasias
- Barrett's esophagus
- Esophageal stricture
- Gastric mass
- Any other subject characteristic that would prevent the successful insertion of a ReShape Duo™ or that in the opinion of the Investigator preclude safe use of the ReShape Duo™
Sites / Locations
- Scottsdale Healthcare
- Hamilton Medical Center
- Marquette General Surgical Weight Loss Center
- University of Minnesota/Department of Gastrointestinal Surgery
- Washington University in St. Louis
- Greenville Hospital System
- Midsouth Bariatrics
- University of TX Health Science Center at Houston
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
ReShape Duo Balloon
Sham Comparator
Arm Description
ReShape Duo Balloon
Sham Comparator
Outcomes
Primary Outcome Measures
Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24
An inferential test of whether the difference in the mean %EWL between the Treatment and Control groups at 24 weeks was significantly greater than a superiority margin 7.5%.
Treatment Group Responder Rate Dichotomized at 25% EWL
An inferential test of whether the percentage of participants in the Treatment Group with a weight loss of >25% EWL at 24 weeks was significantly greater than 35%.
Secondary Outcome Measures
Weight Loss Maintenance Six Months Following Device Removal
Assess whether significantly greater than 50% of treatment subjects maintained 40% of their excess weight loss at 48 weeks.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01673698
Brief Title
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
Official Title
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ReShape Lifesciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The REDUCE Pivotal Trial is a pivotal clinical study designed to develop valid scientific evidence regarding the safety and effectiveness of the ReShape Duo® as an adjunct to diet and exercise in the treatment of obese subjects with one or more obesity-related comorbid conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, weight loss
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
326 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ReShape Duo Balloon
Arm Type
Active Comparator
Arm Description
ReShape Duo Balloon
Arm Title
Sham Comparator
Arm Type
Sham Comparator
Arm Description
Sham Comparator
Intervention Type
Device
Intervention Name(s)
ReShape Duo balloon
Intervention Type
Other
Intervention Name(s)
Diet counseling
Intervention Type
Other
Intervention Name(s)
Exercise counseling
Primary Outcome Measure Information:
Title
Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24
Description
An inferential test of whether the difference in the mean %EWL between the Treatment and Control groups at 24 weeks was significantly greater than a superiority margin 7.5%.
Time Frame
Week 24
Title
Treatment Group Responder Rate Dichotomized at 25% EWL
Description
An inferential test of whether the percentage of participants in the Treatment Group with a weight loss of >25% EWL at 24 weeks was significantly greater than 35%.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Weight Loss Maintenance Six Months Following Device Removal
Description
Assess whether significantly greater than 50% of treatment subjects maintained 40% of their excess weight loss at 48 weeks.
Time Frame
48 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients 21 to 60 years of age
Body Mass Index (BMI) ≥ 30 kg/m^2 and ≤ 40 kg/m^2
At least 5 years of obesity (with BMI ≥ 30)
Stable weight, defined as a subject who has not gained or lost ≥ 5% of body weight in the 3 months preceding the screening assessment
Failure to lose weight, within the 36 months preceding the screening date, after participation in either of the following:
A medically or commercially supervised weight loss program involving regular counseling regarding both diet and exercise.
Use of a United States Food and Drug Administration (FDA)-approved diet drug
The presence of one or more obesity-related comorbid conditions
Willing and able to provide Informed Consent
Willing and able to comply with study procedures and visit schedules as specified by the protocol
If female, the patient must
be postmenopausal for at least 1 year OR
be surgically sterile, OR
if of child bearing potential, must be practicing birth control, be willing to avoid pregnancy for the year of study participation, have a negative serum pregnancy test at screening, and a negative urine pregnancy test at baseline
Residing within a reasonable distance from the Investigator's treating office and able and willing to travel to the Investigator's office to complete all routine follow-up visits.
Exclusion criteria:
History of and/or ongoing clinically significant conditions or disorders of the gastrointestinal (GI) tract
Clinically significant and uncontrolled/unstable hepatic, reproductive, gastrointestinal, renal, hematologic, pulmonary, neurologic, psychiatric, respiratory, endocrine, or cardiovascular system diseases
Significant acute and/or chronic infections of any kind.
Severe coagulopathy, hepatic insufficiency or cirrhosis
Uncontrolled or severe asthma, or any asthma requiring or likely to require inhaled steroid therapy during the anticipated duration of trial participation
Severe obstructive sleep apnea
Incompletely controlled hypothyroidism or hyperthyroidism
Severe systemic disease [consistent with an ASA (American Society of Anesthesia) Physical Status Classification Score of 3 or greater]
Eating disorders, especially binge eating
Inability to walk 200 yards without assistance
Known allergies to any of the device materials or accessories, i.e. silicone, methylene blue, corn starch
Active drug or alcohol addiction within 12 months of enrollment
Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of requiring insulin treatment in the following 12 months
Depressive disorder with total Beck Depression Inventory (BDI) score > 16 points, and/or BDI affective subscale score > 7 points at screening
Ongoing treatment, or anticipated need for such treatment, with anticoagulants, known gastric irritants such as aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs) or agents that can promote gastrointestinal bleeding, within 1 month prior to enrollment, or unwillingness to forego these medications during the study period
Participation within 60 days of screening date in previous or ongoing clinical trial or current usage of an investigational drug or device
Any use of an intragastric device prior to this study.
Genetically caused obesity, such as Prader-Willi syndrome
Any prior bariatric surgery or likely to undergo bariatric surgery during study follow-up period
Concomitant use of, or unwillingness to avoid any use of, weight loss medications, weight loss supplements, weight loss herbal preparations and/or participation in any non-study-related organized weight loss program (commercial or medical) at any time during the study, including online or smart phone applications to track or modify food intake, exercise regimens or weight
Chronic opiate use (> 3 months continuous use) or likely need for opiate use during study participation
Contraindication or allergy to, or unwillingness to use, proton pump inhibitor medication throughout study follow-up duration-Pregnancy, breast feeding, or intention of becoming pregnant during the study
Any screening laboratory values outside of the normal range deemed clinically significant by the Investigator
Anemia defined as either:
Hemoglobin (Hgb) value for females of < 11.0 g/dl, for males < 12.0 g/dl
Abnormal red cell indices and iron deficiency
Smoking cessation within 3 months of study entry or plans to quit smoking during the study
Major surgery, open biopsy or significant traumatic injury within 3 months prior to enrollment.
History of significant adverse experience with sedation or anesthesia
Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with study procedures
Any condition that, in the opinion of the Investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements, including:
Inability or unwillingness to sign the patient informed consent document.
Inability to participate in all necessary study activities due to physical or mental limitations.
Inability or unwillingness to return for all required follow-up visits.
Employees/family members of ReShape Medical® or any of its affiliates or contractors
Employees/family members of the Investigator, sub-Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed
An immediate family member (by marriage or blood relationship) of another subject already enrolled in the REDUCE Pivotal Trial
Endoscopic exclusion criteria:
Peptic ulcerations
Clinically significant hiatal hernia (> 3 cm)
Patulous pyloric channel
Erosive esophagitis
Varices
Angiectasias
Barrett's esophagus
Esophageal stricture
Gastric mass
Any other subject characteristic that would prevent the successful insertion of a ReShape Duo™ or that in the opinion of the Investigator preclude safe use of the ReShape Duo™
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Lehmann, MD, MPH
Organizational Affiliation
Lehmann Consulting
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jaime Ponce, MD
Organizational Affiliation
Hamilton Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Scottsdale Healthcare
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Facility Name
Hamilton Medical Center
City
Dalton
State/Province
Georgia
ZIP/Postal Code
30720
Country
United States
Facility Name
Marquette General Surgical Weight Loss Center
City
Marquette
State/Province
Michigan
ZIP/Postal Code
49855
Country
United States
Facility Name
University of Minnesota/Department of Gastrointestinal Surgery
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Washington University in St. Louis
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Greenville Hospital System
City
Simpsonville
State/Province
South Carolina
ZIP/Postal Code
29680
Country
United States
Facility Name
Midsouth Bariatrics
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Name
University of TX Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
We'll reach out to this number within 24 hrs